Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + XELOX + SCRT for MSS Locally Advanced Rectal Cancer
NCT07594925Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- May 2026
- Primary completion
- Jun 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sintilimab in rectal cancer (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Disease-Free Survival at 36 months. Started May 2026; status: recruiting.
02
Drugs
sintilimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07594925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07594925.